VistaGen Therapeutics, Inc.

NasdaqCM:VTGN Stock Report

Mkt Cap: US$62.1m

VistaGen Therapeutics Management

How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Shawn Singh (59 yo)





Mr. Shawn K. Singh, J.D. has been the Chief Executive Officer at VistaGen Therapeutics, Inc., since August 20, 2009. Mr. Singh serves as the Chief Business Officer and General Counsel at Cato Research Ltd....

CEO Compensation Analysis

How has Shawn Singh's remuneration changed compared to VistaGen Therapeutics's earnings?
DateTotal Comp.SalaryCompany Earnings
Sep 30 2022n/an/a


Jun 30 2022n/an/a


Mar 31 2022US$1mUS$563k


Dec 31 2021n/an/a


Sep 30 2021n/an/a


Jun 30 2021n/an/a


Mar 31 2021US$1mUS$511k


Dec 31 2020n/an/a


Sep 30 2020n/an/a


Jun 30 2020n/an/a


Mar 31 2020US$934kUS$498k


Dec 31 2019n/an/a


Sep 30 2019n/an/a


Jun 30 2019n/an/a


Mar 31 2019US$951kUS$466k


Dec 31 2018n/an/a


Sep 30 2018n/an/a


Jun 30 2018n/an/a


Mar 31 2018US$1mUS$425k


Dec 31 2017n/an/a


Sep 30 2017n/an/a


Jun 30 2017n/an/a


Mar 31 2017US$1mUS$385k


Dec 31 2016n/an/a


Sep 30 2016n/an/a


Jun 30 2016n/an/a


Mar 31 2016US$2mUS$348k


Compensation vs Market: Shawn's total compensation ($USD1.18M) is above average for companies of similar size in the US market ($USD724.43K).

Compensation vs Earnings: Shawn's compensation has been consistent with company performance over the past year.

Leadership Team

Shawn Singh
CEO & Director13.5yrsUS$1.18m0.38%
$ 235.6k
Jerrold Dotson
Chief Financial Officer11.42yrsUS$712.11k0.051%
$ 31.5k
Reid Adler
Chief Corporate Development & Legal Officer0.75yrno data0.16%
$ 100.4k
Joshua Prince
Senior Vice President of Business Operations0.25yrno datano data
Mark Flather
Vice President of Investor Relationsno datano datano data
Trisha Fitzmaurice
Vice President of Human Resourcesno datano datano data
Allen Cato
Senior Vice President of Development Operationsno datano datano data
Mark Ginski
Senior VP and Head of Chemistry2yrsno datano data
Jaakko Lappalainen
Senior Vice President of Medical Research & Pharmacovigilanceno datano datano data
Jessica Haskell
VP, Associate General Counsel & Corporate Secretary0.50yrno datano data


Average Tenure


Average Age

Experienced Management: VTGN's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Shawn Singh
CEO & Director23.08yrsUS$1.18m0.38%
$ 235.6k
Jon Saxe
Independent Chairman23.08yrsUS$160.64k0.027%
$ 16.7k
Jerry Gin
Independent Director6.92yrsUS$160.95k0.19%
$ 120.0k
Gordon Keller
Chairman of Scientific Advisory Board0.17yrno datano data
Thomas Laughren
Member of Clinical & Regulatory Advisory Board6.92yrsno datano data
Maurizio Fava
Member of Clinical & Regulatory Advisory Board7.33yrsno datano data
Michael Liebowitz
Member of CNS Clinical and Regulatory Advisory Board4.33yrsno datano data
Mark Steven Wallace
Member of Clinical & Regulatory Advisory Board5.58yrsno datano data
Gerard Sanacora
Member of Clinical & Regulatory Advisory Board8yrsno datano data
Mary Rotunno
Independent Director1.58yrsUS$305.50k0%
$ 0
Ann Cunningham
$ 0
Sanjay Mathew
Member of Clinical & Regulatory Advisory Board6.92yrsno datano data


Average Tenure


Average Age

Experienced Board: VTGN's board of directors are considered experienced (6.9 years average tenure).